A Multicenter, Open-label, Phase 3 Extension Study to Evaluate the Long-term Efficacy and Safety in Participants Who Are Currently on Treatment in a Belzutifan Study (LITESPARK-043)

Researchers are looking for new ways to treat advanced solid tumors and von Hippel-Lindau (VHL)-related tumors:
* Advanced means the cancer has spread to other parts of the body (metastatic) or cannot be removed with surgery
* Solid tumors are cancers mostly in body organs and tissues, not in the blood or other body liquids
* VHL-related tumors are tumors caused by VHL disease. VHL disease is passed down from parents to children and people with VHL disease have a higher chance of getting certain types of cancer
Researchers want to learn about the long-term effects of a trial medicine called belzutifan. Belzutifan, also called MK-6482, is designed to block a protein that helps tumors grow and survive. This is an extension trial, which means only people who were in certain other belzutifan trials (called parent trials) may be able to join. The goal of this trial is to learn how long people live after they start taking belzutifan.

开始日期2026-03-11

申办/合作机构

Merck Sharp & Dohme LLC

NCT07123090

/ Not yet recruiting临床2期IIT

A Phase 2 Study of Sasanlimab, Palbociclib and Axitinib in Metastatic Renal Cell Carcinoma - SPARCC

The goal of this research study is to evaluate how well and safely the study drugs sasanlimab, palbociclib, and axitinib work for treatment of participants with advanced clear cell renal cell carcinoma (ccRCC) or translocation renal cell carcinoma (tRCC).
The name of the study drugs involved in this research study is:
* Sasanlimab (a type of monoclonal antibody)
* Palbociclib (a type of kinase inhibitor)
* Axitinib (a type of Vascular endothelial growth factor inhibitor)

开始日期2026-02-01

申办/合作机构

Dana-Farber Cancer Institute, Inc.

[+1]

NCT07347600

/ RecruitingN/A

A Prospective Non-interventional Study to Evaluate the Effectiveness and Safety of Inavolisib in Patients With Endocrine-resistant, PIK3CA-mutated, Hormone Receptor-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer (reaINAVO)

The main purpose of this study is to evaluate the effectiveness of inavolisib based regimen in participants with endocrine-resistant, phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha gene (PIK3CA)-mutated, hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) locally advanced or metastatic breast cancer (LA/mBC), following on or after completing adjuvant endocrine therapy in routine clinical practice in China.

开始日期2026-01-21

申办/合作机构

Roche Holding AG

100 项与哌柏西利相关的临床结果

登录后查看更多信息

100 项与哌柏西利相关的转化医学

登录后查看更多信息

100 项与哌柏西利相关的专利（医药）

登录后查看更多信息

2,883

项与哌柏西利相关的文献（医药）

2026-12-01·MOLECULAR BIOLOGY REPORTS

Possible TLR-mediated immunostimulatory effect of Palbociclib in breast cancer

Article

作者: Sağ, Sevda ; Tomatir, Ayse Gaye ; Ergezgin, Huriye ; Bayav, Ibrahim ; Dodurga, Yavuz

BACKGROUND:

Palbociclib, which exerts its effect by inhibiting the cell cycle in cancer cells, is a CDK inhibitor used in the treatment of ER+/HER- breast cancer. In this study, we aimed to investigate the effect of Pablosiklib on TLR, which plays an important role in the immune response, in MCF-7 (ER+/HER2-) and MDA-MB-231 (ER-/PR-/HER2-) cell lines.

METHODS AND RESULTS:

The expression levels of TLR 1-10 genes, cell cycle-related genes (CDK4/6), and genes involved in the apoptotic pathway (Bcl-2, Bax, Cas-3) in MCF-7 and MDA-MB-231 cells treated with palbociclib were evaluated using the real-time PCR (qRT-PCR) method. Additionally, the levels of total retinoblastoma (RB) and phosphorylated retinoblastoma (pRB) proteins were analyzed using the Western blot method. CDK4/6 and pRB expression decreased in MCF-7 and MDA-MB-231 cells treated with palbociclib. Bax and Cas-3 expression increased, while Bcl-2 expression decreased. Changes in TLR expression were also observed.

CONCLUSIONS:

We believe that palbociclib not only stops the cell cycle and induces apoptosis in breast cancer cells, but also activates the immune response via TLRs.

2026-04-01·INTERNATIONAL JOURNAL OF CANCER

Optimizing the integration of modern systemic therapies and advanced radiotherapy techniques in breast cancer management: An expert opinion from the Institut Curie Breast Radiotherapy Group

Review

作者: Cao, Kim ; Loap, Pierre ; Kirova, Youlia ; Fourquet, Alain ; Cheptea, Cezara ; Allali, Sofiane

Abstract:

The integration of modern systemic therapies with radiotherapy (RT) represents a promising strategy in breast cancer management, enhancing both locoregional control and systemic disease outcomes. This expert consensus from the Institut Curie Breast Radiotherapy Group focuses exclusively on modern systemic agents, synthesizing current evidence on the concurrent administration of human epidermal growth factor receptor 2‐targeted agents (trastuzumab, pertuzumab, trastuzumab emtansine, trastuzumab deruxtecan), cyclin‐dependent kinase 4 and 6 inhibitors (palbociclib, ribociclib), immunotherapies (pembrolizumab), poly(ADP‐ribose) polymerase inhibitors (olaparib), and new antibody‐drug conjugates (sacituzumab govitecan). Drawing from extensive clinical experience, including retrospective and prospective studies conducted at Institut Curie, this review provides a comprehensive analysis of the feasibility and safety of these novel combinations, ensuring an evidence‐based approach to optimizing breast cancer treatment strategies. In addition to systemic therapy considerations, this review highlights the importance of advanced RT techniques, including proton therapy, isocentric lateral decubitus positioning, and volumetric modulated arc therapy with deep inspiration breath hold, which play a crucial role in minimizing cardiac and pulmonary toxicities, particularly in patients receiving cardiotoxic agents or those with predisposing risk factors. By integrating both systemic advancements and optimized radiation delivery, this review provides a practical framework for the safe and effective combination of modern breast cancer therapies.

2026-04-01·BREAST

Effectiveness comparison of first-line CDK4/6 inhibitors in patients with hormone-positive HER2-negative advanced breast cancer according to tumor histology: a sub-analysis of the real-world, multicenter, Italian study PALMARES-2

Article

作者: Zurlo, Christian ; Chiappe, Edoardo ; Mariani, Luigi ; Sartori, Donata ; Pedersini, Rebecca ; Jacobs, Flavia ; Gennari, Alessandra ; Armani, Giovanna ; De Angelis, Carmine ; Criscitiello, Carmen ; Giordano, Monica ; Vernieri, Claudio ; Menichetti, Alice ; Sirico, Marianna ; Griguolo, Gaia ; Schianca, Ambra Carnevale ; Toss, Angela ; Rizzo, Gianpiero ; Ligorio, Francesca ; Marra, Antonio ; Capasso, Camilla ; Tagliaferri, Barbara ; Provenzano, Leonardo ; Scagnoli, Simone ; Guarneri, Valentina ; Curigliano, Giuseppe ; Arpino, Grazia ; Dieci, Maria Vittoria ; Faso, Valeria ; Piras, Marta ; Botticelli, Andrea ; Munzone, Elisabetta ; Generali, Daniele ; Fotia, Giuseppe ; La Verde, Nicla ; Pisegna, Simona ; Giuliano, Mario ; De Monte, Matteo ; Mazzoli, Giacomo ; Pruneri, Giancarlo ; Lambertini, Matteo ; Zambelli, Alberto

INTRODUCTION:

Invasive lobular breast cancer (ILC) is the second most common breast cancer subtype, with distinctive biological and epidemiologic features. Although phase III trials of cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) in hormone receptor-positive, HER2-negative advanced breast cancer (HR+/HER2-aBC) included patients with ILC, their real-world effectiveness in this population remains poorly characterized.

MATERIAL AND METHODS:

In this sub-analysis of the multicenter, real-world PALMARES-2 study (NCT06805812), we assessed the predictive and prognostic value of lobular histology in HR+/HER2-aBC treated with first-line endocrine therapy (ET) plus CDK4/6i. The primary endpoint was real-world progression-free survival (rwPFS). Associations between histology and outcomes were adjusted for 15 covariates using multivariable Cox-regression and inverse probability of treatment weighting.

RESULTS:

Among 1982 patients, 367 (18.5 %) had ILC and 1481 (74.7 %) non-special type (NST). Median follow-up was 29.8 and 31.2 months, respectively. ILC was associated with shorter rwPFS versus NST (adjusted hazard ratio [aHR]: 1.24, 95 %CI:1.04-1.47, P=0.017). Palbociclib efficacy was not affected by lobular histology (P for interaction = 0.553) while abemaciclib was less effective in ILC (P = 0.009). All three CDK4/6i achieved similar rwPFS in ILC (ribociclib vs palbociclib: aHR: 1.01, 95 %CI: 0.67-1.45, P = 0.949; abemaciclib vs palbociclib: aHR: 1.13, 95 %CI: 0.75-1.71, P = 0.551; abemaciclib vs ribociclib: aHR: 1.15, 95 %CI: 0.73-1.80, P = 0.549).

CONCLUSIONS:

Tumor histology affects the real-world effectiveness of first line ET plus CDK4/6i. In ILC, all three CDK4/6i performed similarly; therefore, treatment selection should prioritize tolerability, manageability, drug-drug interactions, and patient preferences.

1,561

项与哌柏西利相关的新闻（医药）

2026-02-22

·道道之道

【本周医刊】2026年第8周医学期刊更新

2026年第8周（2026.02.15-2026.02.21）重要医学期刊论著更新如下： 1.综合期刊 LANCET 题目：Tenecteplase versus standard medical treatment for basilar artery occlusion within 24 h (TRACE-5): a multicentre, prospective, randomised, open-label, blinded-endpoint, superiority, phase 3 trial 翻译：替奈普酶对比标准药物治疗 24 小时内基底动脉闭塞（TRACE‑5）：一项多中心、前瞻性、随机、开放标签、终点盲法、优效性Ⅲ期临床试验题目：Recombinant factor VIIa versus placebo for spontaneous intracerebral haemorrhage within 2 h of symptom onset (FASTEST): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial 翻译：重组凝血因子Ⅶa对比安慰剂用于症状发作2 小时内自发性脑出血（FASTEST）：一项多中心、双盲、随机、安慰剂对照Ⅲ期临床试验题目：Cumulative incidence of advanced breast cancer in women aged 40–49 years in the Japan Strategic Anti-cancer Randomised Trial (J-START) of adjunctive ultrasonography: a prespecified secondary analysis 翻译：日本附加超声筛查抗癌随机试验（J‑START）中40～49岁女性晚期乳腺癌累积发病率：一项预设亚组分析题目：Efimosfermin alfa (BOS-580) once per month in people with metabolic dysfunction-associated steatohepatitis with F2 or F3 fibrosis: results from a 24-week, randomised, double-blind, placebo-controlled, phase 2 trial 翻译：艾菲莫肽 α（BOS‑580）每月一次治疗F2/F3 纤维化代谢相关脂肪性肝炎：一项24 周、随机、双盲、安慰剂对照Ⅱ期临床试验结果 NEW ENGLAND JOURNAL OF MEDICINE 题目：Teclistamab plus Daratumumab in Relapsed or Refractory Multiple Myeloma 翻译：泰莱斯塔单抗联合达雷妥尤单抗治疗复发或难治性多发性骨髓瘤题目：Hematopoietic Stem-Cell Gene Therapy for Cystinosis 翻译：胱氨酸病的造血干细胞基因治疗题目：An Antibody–Oligonucleotide Conjugate for Myotonic Dystrophy Type 1 翻译：用于 1 型强直性肌营养不良的抗体- 寡核苷酸偶联物题目：Transcatheter or Surgical Aortic-Valve Replacement in Low-Risk Patients at 7 Years 翻译：低危患者经导管或外科主动脉瓣置换术后7 年结局 JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION 题目：Expectant Management vs Medication for Patent Ductus Arteriosus in Preterm Infants: The PDA Randomized Clinical Trial 翻译：期待治疗对比药物治疗早产儿动脉导管未闭：PDA随机临床试验题目：Cryopreserved vs Liquid-Stored Platelets for the Treatment of Surgical Bleeding: The CLIP-II Randomized Noninferiority Clinical Trial 翻译：冻存血小板对比液态保存血小板治疗外科出血：CLIP‑II随机非劣效性临床试验题目：Prenatal Exposure to Acid-Suppressive Medications and Risk of Neuropsychiatric Disorders in Children 翻译：产前暴露于抑酸药物与儿童神经精神疾病发病风险的关系 NATURE MEDICINE 题目：Colonoscopy and fecal immunochemical testing versus usual care in diagnostic colorectal cancer screening: the SCREESCO randomized controlled trial 翻译：结肠镜联合粪便免疫化学检测对比常规方案用于结直肠癌诊断性筛查：SCREESCO随机对照试验题目：Predicting onset of symptomatic Alzheimerʼs disease with plasma p-tau217 clocks 翻译：血浆 p-tau217 时钟预测症状性阿尔茨海默病发病题目：Bispecific T cell engagers for treatment-refractory autoimmune connective tissue diseases 翻译：双特异性 T 细胞衔接器用于治疗难治性自身免疫性结缔组织病题目：Deciphering the etiology of the 2024 outbreak of undiagnosed febrile illness in Panzi, Democratic Republic of the Congo 翻译：解析刚果民主共和国潘齐市 2024 年不明原因发热疫情的病因题目：Effects of a comprehensive antibiotic stewardship program on antibiotic prescribing for acute respiratory infections in rural facilities: a cluster randomized trial 翻译：综合性抗生素管理项目对基层医疗机构急性呼吸道感染抗生素处方的影响：一项整群随机试验题目：A short-acting psychedelic intervention for major depressive disorder: a phase IIa randomized placebo-controlled trial 翻译：短效致幻剂干预治疗重度抑郁症：一项Ⅱa期随机安慰剂对照试验题目：A quantitative DOPA decarboxylase biomarker for diagnosis in Lewy body disorders 翻译：用于路易体病诊断的定量多巴脱羧酶生物标志物 BMJ-BRITISH MEDICAL JOURNAL 题目：Menopausal hormone therapy and long term mortality 翻译：绝经激素治疗与长期死亡率题目：Vitamin D supplementation before in vitro fertilisation in women with polycystic ovary syndrome 翻译：多囊卵巢综合征女性体外受精前的维生素D 补充 INNOVATION（本周无更新） LANCET DIGITAL HEALTH（本周无更新） NPJ DIGITAL MEDICINE 题目：A large-scale benchmark for evaluating large language models on medical question answering in Romanian 翻译：面向罗马尼亚语医学问答的大语言模型大规模基准评测题目：Artificial intelligence–enhanced microsurgical training: a systematic review 翻译：人工智能增强的显微外科培训：一项系统评价题目：Defining operational safety in clinical artificial intelligence systems 翻译：临床人工智能系统中操作性安全性的定义题目：CancerLLM: a large language model in cancer domain 翻译：CancerLLM：一款肿瘤领域专用大语言模型题目：Robust and interpretable unit level causal inference in neural networks for pediatric myopia 翻译：基于神经网络的儿童近视个体水平稳健可解释因果推断题目：Large language models in systematic review and meta-analysis of surgical treatments for vaginal vault prolapse 翻译：大语言模型在阴道穹隆脱垂手术治疗系统评价与Meta 分析中的应用题目：Hierarchical deep learning pipeline for robust cervical parameter measurement in radiographs with C7 obscuration 翻译：针对 C7 节段遮挡X 光片的稳健性颈椎参数测量分层深度学习流程题目：Benchmarking large language model-based agent systems for clinical decision tasks 翻译：面向临床决策任务的大语言模型智能体系统基准测试题目：Computer vision applications in vascular surgery: a systematic review and critical appraisal 翻译：计算机视觉在血管外科中的应用：一项系统评价与批判性评价题目：Empowering genetic discoveries and cardiovascular risk assessment by predicting electrocardiograms from genotype 翻译：通过基因型预测心电图以助力遗传学发现与心血管风险评估题目：BRIDGE pilot study: a bilateral regulatory investigation of data governance and exchange 翻译：BRIDGE 试点研究：一项关于数据治理与数据交换的双边监管调查题目：Artificial intelligence-based incident analysis and learning system to enhance patient safety and improve treatment quality 翻译：基于人工智能的不良事件分析与学习系统：提升患者安全与治疗质量题目：Health economic simulation modeling of an AI-enabled clinical decision support system for coronary revascularization 翻译：面向冠脉血运重建的人工智能临床决策支持系统卫生经济学模拟建模题目：A deep learning model integrating structured data and clinical text for predicting atrial fibrillation recurrence 翻译：整合结构化数据与临床文本的深度学习模型预测心房颤动复发题目：Risk Prediction of Chronic Kidney Disease Progression in Type 2 Diabetes Mellitus Across Diverse Populations 翻译：不同人群中 2 型糖尿病患者慢性肾脏病进展的风险预测题目：Randomized-controlled trial of skills-based vr vs. distraction vr vs. sham VR for chronic low back pain 翻译：基于技能的虚拟现实、分散注意力虚拟现实与假虚拟现实治疗慢性下腰痛的随机对照试验题目：Bridging radiology and pathology: domain-generalized cross-modal learning for clinical 翻译：桥接放射学与病理学：面向临床的域泛化跨模态学习 2.肿瘤学 CA-A CANCER JOURNAL FOR CLINICIANS（本周无更新） ANNALS OF ONCOLOGY 题目：Cabozantinib plus nivolumab and ipilimumab in previously untreated, advanced renal cell carcinoma: final results and biomarker analyses from the phase III COSMIC-313 study 翻译：卡博替尼联合纳武利尤单抗 + 伊匹木单抗治疗初治晚期肾细胞癌：Ⅲ期COSMIC-313 研究最终结果与生物标志物分析题目：Learning the Forest Before the Trees: Artificial Intelligence and Thymic Tumor Pathology 翻译：先见森林后见树木：人工智能与胸腺肿瘤病理学题目：ESMO Adaptation of Lines of Systemic Therapy (EnLiST): a consensus framework for standardising the designation of lines of therapy in solid tumours 翻译：ESMO 系统性治疗线数适配方案（EnLiST）：实体瘤治疗线数定义标准化共识框架题目：Doubting T(h)OMAS: Has the era of precision oncology arrived in uterine leiomyosarcoma? 翻译：质疑 T (h) OMAS：精准肿瘤学时代是否已降临子宫平滑肌肉瘤？题目：PET/CT-Guided Management of Immune Checkpoint Blockade and Post-Treatment Multi-Modal Profiling in Long-Term Responders with Metastatic Lung Cancer in the National Network Genomic Medicine Lung Cancer Germany (nNGM) 翻译：德国国家肺癌基因组医学网络（nNGM）：转移性肺癌长期应答者的PET/CT 指导下免疫检查点阻断治疗管理及治疗后多组学分析 JOURNAL OF CLINICAL ONCOLOGY 题目：Hepatic Arterial Infusion Pump Chemotherapy in Patients With Unresectable Intrahepatic Cholangiocarcinoma—PUMP-2 Trial 翻译：肝动脉灌注泵化疗治疗不可切除肝内胆管癌——PUMP‑2 试验题目：BRUIN CLL-313: Randomized Phase III Trial of Pirtobrutinib Versus Bendamustine Plus Rituximab in Untreated Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma 翻译：BRUIN CLL‑313：吡托布鲁替尼对比苯达莫司汀联合利妥昔单抗治疗初治慢性淋巴细胞白血病/ 小淋巴细胞淋巴瘤的随机Ⅲ期试验题目：Pirtobrutinib Versus Ibrutinib in Treatment-Naïve and Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma 翻译：吡托布鲁替尼对比伊布替尼治疗初治及复发/ 难治性慢性淋巴细胞白血病/ 小淋巴细胞淋巴瘤题目：Extended Endocrine Therapy Following 5 Years of Adjuvant Luteinizing Hormone-Releasing Hormone Agonist in Premenopausal Patients With Node-Positive, Hormone Receptor–Positive Breast Cancer: A Cohort Study 翻译：淋巴结阳性、激素受体阳性绝经前乳腺癌患者接受5 年促黄体生成素释放激素激动剂辅助治疗后的延长内分泌治疗：一项队列研究题目：NCI9673 (Part B): ETCTN Randomized Phase II Study of Nivolumab With or Without Ipilimumab in Refractory, Metastatic Squamous Cell Carcinoma of the Anal Canal 翻译：NCI9673（B部分）：纳武利尤单抗联合或不联合伊匹木单抗治疗难治性转移性肛管鳞状细胞癌的ETCTN 随机Ⅱ期试验 LANCET ONCOLOGY（本周无更新） JOURNAL OF THORACIC ONCOLOGY（本周无更新） JAMA ONCOLOGY 题目：Predictive Role of Circulating Tumor DNA in Stage III Colon Cancer Treated With Celecoxib: A Post Hoc Analysis of the CALGB (Alliance)/SWOG 80702 Phase 3 Randomized Clinical Trial 翻译：循环肿瘤 DNA 在接受塞来昔布治疗的Ⅲ期结肠癌中的预测价值：CALGB（Alliance）/SWOG 80702 Ⅲ期随机临床试验的事后分析题目：Cognitive Impairment and Chemoendocrine vs Endocrine Therapy in Pre- and Postmenopausal Women: A Secondary Analysis of the RxPONDER Randomized Clinical Trial 翻译：绝经前与绝经后女性的认知功能损伤及化疗内分泌治疗对比内分泌治疗：RxPONDER随机临床试验的二次分析题目：Enhancement of Patient-Centered Lung Cancer Screening: The MyLungHealth Randomized Clinical Trial 翻译：以患者为中心的肺癌筛查优化：MyLungHealth 随机临床试验题目：Quadrivalent Human Papillomavirus Vaccine and High-Grade Vulvovaginal Lesions 翻译：四价人乳头瘤病毒疫苗与高级别外阴阴道病变题目：Baseline Fatigue and Severe Toxic Effects in Patients With Cancer Receiving Systemic Therapy 翻译：接受全身治疗的癌症患者基线疲劳程度与严重毒性反应 CANCER RESEARCH 题目：EZH2 Suppression Diversifies Prostate Cancer Lineage Variant Evolution and Lacks Efficacy in Inhibiting Disease Progression 翻译：抑制 EZH2 可增加前列腺癌谱系变异演化多样性，但无法有效抑制疾病进展题目：The Aging Microenvironment Is a Determinant of Immune Exclusion and Metastatic Fate in Pancreatic Cancer 翻译：衰老微环境是胰腺癌免疫排斥与转移命运的决定因素题目：Mitochondrial Transfer Rescues Respiration to Support De Novo Pyrimidine Biosynthesis and Tumor Progression 翻译：线粒体转移可恢复呼吸作用，支持从头嘧啶合成与肿瘤进展题目：Dissection of Gαs and Hedgehog Signaling Cross-talk Reveals Therapeutic Opportunities to Target Hedgehog-Dependent Tumors 翻译：解析 Gαs与Hedgehog 信号通路交互作用，为靶向Hedgehog 依赖性肿瘤提供治疗策略题目：Protumor Macrophage Polarization Mediated by BMP2/4–ACVR1 Signaling Orchestrates an Immunosuppressive Microenvironment during Tumor Initiation 翻译：肿瘤发生阶段，BMP2/4–ACVR1信号介导的促肿瘤巨噬细胞极化构建免疫抑制微环境题目：Tetraspanin 13 Enhances Immune Evasion in Breast Cancer by Promoting MHC-I Degradation 翻译：四次跨膜蛋白 13 通过促进MHC‑I 降解增强乳腺癌免疫逃逸题目：Cancer-Associated Fibroblasts Promote Imatinib Resistance in Gastrointestinal Stromal Tumors through PGK1-Mediated Metabolic Reprogramming 翻译：癌相关成纤维细胞通过 PGK1 介导的代谢重编程促进胃肠道间质瘤对伊马替尼耐药题目：Catalytic Inhibition of p300 Preferentially Targets IRF4 Oncogenic Activity and Tumor Growth in Multiple Myeloma 翻译：p300 催化抑制可优先靶向多发性骨髓瘤中IRF4 致癌活性与肿瘤生长题目：CRISPR-Cas9 Screening Identifies Resistance Mechanisms to KRAS Inhibition in Pancreatic Cancer 翻译：CRISPR‑Cas9 筛选揭示胰腺癌对KRAS 抑制的耐药机制题目：An Extracellular Matrix–Producing Subset of Cancer-Associated Fibroblasts Drives Chemoresistance in Breast Cancer via SRC Activation and G0S2 Upregulation 翻译：一类分泌细胞外基质的癌相关成纤维细胞亚群通过SRC 激活与G0S2 上调驱动乳腺癌化疗耐药题目：Dynamic and Ongoing De Novo L1 Retrotransposition Contributes to Genome Plasticity and Intrapatient Heterogeneity in Ovarian Cancer 翻译：动态且持续的从头 L1 逆转录转座促进卵巢癌基因组可塑性与患者内异质性 CLINICAL CANCER RESEARCH 题目：Palbociclib, Trastuzumab, and Endocrine Therapy in Pretreated HER2-Positive and PAM50 Luminal Advanced Breast Cancer: Randomized Phase II, SOLTI-1303 PATRICIA Trial 翻译：哌柏西利、曲妥珠单抗联合内分泌治疗既往接受过治疗的HER2 阳性、PAM50腔面型晚期乳腺癌：SOLTI‑1303 PATRICIA 随机Ⅱ期临床试验题目：FDG-PET–Based Selective Deescalation of Chemoradiation in Human Papillomavirus–Related Oropharyngeal Squamous Cell Carcinoma: A Multicenter Phase II Trial 翻译：基于 FDG‑PET 选择性降阶梯放化疗治疗人乳头瘤病毒相关口咽鳞状细胞癌：一项多中心Ⅱ期临床试验题目：T-Cell Receptor and Immune Gene Expression Pharmacodynamics for Durvalumab Alone and with Tremelimumab or Bevacizumab in Unresectable Hepatocellular Carcinoma 翻译：度伐利尤单抗单药或联合曲美木单抗 / 贝伐珠单抗治疗不可切除肝细胞癌的T 细胞受体与免疫基因表达药效学研究题目：HBV Reactivation in Patients with Hepatocellular Carcinoma Treated with PD-1/-L1 Antibodies and Concurrent Antiviral Prophylaxis Agents: A Prospective Observational Study 翻译：PD‑1/PD‑L1 抗体联合预防性抗病毒药物治疗肝细胞癌患者的乙肝病毒再激活：一项前瞻性观察性研究题目：Anti–LAG-3 Antibody LBL-007 plus Tislelizumab and Chemotherapy as First-Line Therapy for Advanced Nasopharyngeal Carcinoma: A Multicenter Phase 2 Trial 翻译：抗 LAG‑3 抗体LBL‑007 联合替雷利珠单抗与化疗作为晚期鼻咽癌一线治疗：一项多中心Ⅱ期临床试验题目：Molecular Profiling and Tumor Biomarker Analysis of GOG281/LOGS: A Positive Late-Phase Trial of Trametinib for Recurrent/Persistent Low-Grade Serous Ovarian Carcinoma 翻译：GOG281/LOGS 研究的分子谱与肿瘤生物标志物分析：曲美替尼治疗复发性/ 持续性低级别浆液性卵巢癌的阳性晚期试验题目：Investigating Early Kinetics in Plasma ctDNA and Peripheral T-cell Receptor Repertoire to Predict Treatment Outcomes to PD-1 Inhibitors in Head and Neck Squamous Cell Carcinoma 翻译：血浆 ctDNA 早期动力学与外周T 细胞受体库预测头颈部鳞状细胞癌PD‑1 抑制剂治疗疗效题目：Minimal Residual Disease Enhances Prognostic Stratification beyond Pathologic Response in Resectable Non–Small Cell Lung Cancer 翻译：可切除非小细胞肺癌中，微小残留病可在病理缓解之外进一步提升预后分层效能题目：Improving a Plasma Biomarker Panel for Early Detection of Pancreatic Ductal Adenocarcinoma with Aminopeptidase N (ANPEP) and Polymeric Immunoglobulin Receptor (PIGR) 翻译：联合氨基肽酶 N（ANPEP）与多聚免疫球蛋白受体（PIGR）优化胰腺导管腺癌早期检测血浆生物标志物panel 题目：Germline Pathogenic Variant Prediction Model for Tumor-Only Sequencing Based on Japanese Clinicogenomic Database 翻译：基于日本临床基因组数据库的仅肿瘤测序胚系致病变异预测模型题目：Upregulation of TNFR2 Precedes TOX Expression by Exhausted T cells and Restricts Antitumor and Antiviral Immunity 翻译：TNFR2 上调先于耗竭T 细胞TOX 表达，并抑制抗肿瘤与抗病毒免疫题目：Additive Clinical Utility of Microsatellite Instability and Tumor Mutational Burden to Predict Immune Checkpoint Inhibitor Effectiveness in Metastatic Castration-Resistant Prostate Cancer 翻译：微卫星不稳定性与肿瘤突变负荷在预测转移性去势抵抗性前列腺癌免疫检查点抑制剂疗效中的附加临床价值题目：A Generative Foundation Model for Scalable Cytology Image Synthesis in AI-Powered Diagnostics 翻译：用于 AI 辅助诊断中可规模化细胞学图像合成的生成式基础模型 JOURNAL OF THE NATIONAL CANCER CENTER 题目：Clinicopathologic, genetic and immune cell infiltration analysis of colorectal signet ring cell carcinoma with comparison to conventional adenocarcinoma 翻译：结直肠印戒细胞癌的临床病理、遗传学及免疫细胞浸润分析——并与常规腺癌对比 JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE（本周无更新） 3.内分泌学与代谢 LANCET DIABETES & ENDOCRINOLOGY 题目：Effect of surgical versus conservative management on cardiovascular outcomes in patients with bilateral adrenal tumours and cortisol excess: an international, retrospective cohort study 翻译：手术治疗对比保守治疗对双侧肾上腺肿瘤合并皮质醇增多患者心血管结局的影响：一项国际回顾性队列研究题目：3 months vs 12 months of romosozumab for postmenopausal osteoporosis (LIDA): an open-label, non-inferiority, randomised controlled trial 翻译：罗莫佐单抗治疗绝经后骨质疏松症 3 个月对比12 个月（LIDA）：一项开放标签、非劣效性随机对照试验题目：Temporal changes and genetic susceptibility to type 2 diabetes (1984–2019; HUNT): a longitudinal, population-based study 翻译：2 型糖尿病的时间变化趋势与遗传易感性（1984–2019；HUNT研究）：一项基于人群的纵向研究题目：Efficacy and safety of inclisiran in adolescents with heterozygous familial hypercholesterolaemia (ORION-16): a two-part, randomised, multicentre clinical trial 翻译：英克西兰治疗杂合子家族性高胆固醇血症青少年的有效性与安全性（ORION‑16）：一项两阶段、多中心随机临床试验 DIABETES CARE 题目：The Effect of Midpregnancy Screening for Gestational Diabetes Mellitus on Pregnancy Outcomes: The TESGO Randomized Controlled Trial 翻译：妊娠中期妊娠期糖尿病筛查对妊娠结局的影响：TESGO随机对照试验题目：Generalizability of Progression Risk in the TN-10 Trial to a European Population With or Without a First-Degree Relative With Type 1 Diabetes 翻译：TN-10 研究中进展风险在有无1 型糖尿病一级亲属的欧洲人群中的外推性题目：Safety and Feasibility of a Fully Automated Insulin Delivery System: FCL@Home, a Multicenter Randomized Clinical Trial in Individuals With Type 1 Diabetes 翻译：全自动胰岛素输注系统的安全性与可行性：FCL@Home——一项针对1 型糖尿病患者的多中心随机临床试验题目：Impact of Maternal Diabetes in Pregnancy on Newborn IgG Antibody Repertoire and Infection Risk in the First 6 Months of Life 翻译：孕期母体糖尿病对新生儿 IgG 抗体谱及出生后6 个月内感染风险的影响题目：MiniMed 780G Advanced Hybrid Closed-Loop System Use During Days Without User-Initiated Boluses 翻译：无用户主动推注期间 MiniMed 780G 高级混合闭环系统的使用情况题目：Metabolic Factors Modulating the Connection Between Diabetes and Pulmonary Alterations 翻译：调控糖尿病与肺部改变之间关联的代谢因素题目：Interoceptive Awareness Moderates the Relationship Between Hypoglycemia Exposure and Symptom Recognition in Adults With Type 1 Diabetes 翻译：内感受感知调节 1 型糖尿病成人低血糖暴露与症状识别之间的关系题目：Associations of Moderate-to-Vigorous Physical Activity Timing With Type 2 Diabetes Incidence in UK Biobank and Prevalent Glycemic Measures in NHANES 翻译：英国生物银行中中高强度体力活动时间与2 型糖尿病发病风险的关联及NHANES 中血糖相关指标的横断面分析题目：Soluble Urokinase Plasminogen Activator Receptor (suPAR) Mediates the Impact of Diabetes on Adverse Outcomes in Coronary Artery Disease 翻译：可溶性尿激酶型纤溶酶原激活物受体（suPAR）介导糖尿病对冠心病不良结局的影响题目：Gout-Related Medication Use After Initiating Sodium–Glucose Cotransporter 2 Inhibitors in Patients With Gout and Type 2 Diabetes: Population-Based Target Trial Emulation Studies 翻译：痛风合并 2 型糖尿病患者启动钠- 葡萄糖协同转运蛋白2 抑制剂后痛风相关药物使用：基于人群的目标试验模拟研究题目：A Comparison of Diet and Exercise During Pregnancy in Women With and Without Type 1 Diabetes Followed in the Environmental Determinants of Islet Autoimmunity (ENDIA) Study 翻译：胰岛自身免疫环境决定因素（ENDIA）研究中1 型糖尿病与非1 型糖尿病孕妇孕期饮食与运动的比较题目：Chronic Kidney Disease and Risk of Diabetic Ketoacidosis in Type 1 Diabetes 翻译：慢性肾脏病与 1 型糖尿病糖尿病酮症酸中毒风险的关系题目：Assessing Time Below Range as a Predictor of Severe Hypoglycemia: Insights From Six Clinical Trials 翻译：评估血糖低于范围时间作为严重低血糖的预测因子：六项临床试验的启示题目：Global, Regional, and National Estimates of Undiagnosed Diabetes in Adults: Findings From the 2025 IDF Diabetes Atlas 翻译：全球、区域及国家层面成人未确诊糖尿病估计：2025年IDF 糖尿病图谱结果题目：Sex Hormones and Cardiovascular Risk in Type 2 Diabetes: Cohort Study of the Look AHEAD Trial 翻译：2 型糖尿病中性激素与心血管风险：Look AHEAD 试验的队列研究题目：Rapid Postpartum Progression to Diabetes Following Early Antenatal Prediabetes: Evidence From a Multiethnic New Zealand Cohort 翻译：孕期早期 prediabetes 后产后快速进展为糖尿病：新西兰多种族队列研究证据 4.心血管病学 CIRCULATION 题目：Hypertensive Disorders of Pregnancy and Premature Cardiovascular Disease in a Diverse Cohort of Young US Women 翻译：妊娠期高血压疾病与美国多种族年轻女性早发性心血管疾病的关系题目：Polycystic Ovarian Syndrome and the Long-Term Risk of Arrhythmias 翻译：多囊卵巢综合征与心律失常长期发病风险题目：Association of Statin Discontinuation in Pregnancy With Maternal Cardiovascular Health and Birth Outcomes: A Nationwide Cohort Study 翻译：孕期停用他汀类药物与母体心血管健康及分娩结局的关联：一项全国性队列研究题目：Breast Cancer Reveals Latent BMPR2-Related Susceptibility to Pulmonary Hypertension 翻译：乳腺癌揭示潜在的BMPR2相关肺动脉高压易感性 EUROPEAN HEART JOURNAL 题目：Catheter ablation in congenital heart diseases: a French nationwide study 翻译：先天性心脏病的导管消融术：一项法国全国性研究题目：Arrhythmias in congenitally corrected transposition of the great arteries: an international study 翻译：先天性矫正型大动脉转位中的心律失常：一项国际研究题目：Early outcomes of children with univentricular circulation undergoing Fontan surgery: the EuroFontan registry 翻译：单心室循环患儿接受 Fontan 手术的早期结局：EuroFontan注册登记研究题目：Adults with Fontan circulation: prognostic value of exercise pulmonary vascular resistance index 翻译：Fontan 循环成人患者：运动肺血管阻力指数的预后价值 JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY 题目：Menopausal Status Associated With Docetaxel-Induced Vascular Dysfunction in Breast Cancer Patients 翻译：绝经状态与乳腺癌患者多西他赛诱导的血管功能障碍相关题目：Sex-Specific Microaxial Flow Pump Use and Outcomes in Infarct-Related Cardiogenic Shock in the DanGer Shock Trial 翻译：DanGer 休克研究：梗死相关性心源性休克中微型轴流泵的使用及结局存在性别差异 5.胃肠肝病学 LANCET GASTROENTEROLOGY & HEPATOLOGY（本周无更新） JOURNAL OF HEPATOLOGY 题目：Genetic and non-genetic drivers of histological progression and regression in MASLD 翻译：MASLD 组织学进展与逆转的遗传及非遗传驱动因素题目：HBx-induced HSPB1 is a potential therapeutic target owing to its modulation of HBV cccDNA and hepatic immune responses 翻译：HBx 诱导的HSPB1 通过调控HBV cccDNA 与肝脏免疫反应成为潜在治疗靶点题目：Safety and efficacy of REP 2139-Mg in patients with HDV-related advanced liver disease in an international compassionate access program 翻译：国际同情用药项目中 REP 2139-Mg 治疗HDV 相关晚期肝病的安全性与有效性题目：Refining the Baveno VII criteria for clinically significant portal hypertension: An individual patient data meta-analysis 翻译：优化具有临床意义门静脉高压的 Baveno VII 标准：一项个体患者数据荟萃分析题目：Setd4-expressing cells drive regenerative recovery in chronic liver injury 翻译：表达 Setd4 的细胞介导慢性肝损伤的再生修复题目：Strategies to address non-proportional hazards between survival curves - Lessons from phase III trials in hepatocellular carcinoma 翻译：处理生存曲线间非比例风险的策略——来自肝细胞癌Ⅲ期试验的启示题目：HES V2.0 validation and performance compared to GALAD and ASAP in the HEDS cohort 翻译：HEDS 队列中HES V2.0 与GALAD、ASAP的对比验证及性能评估题目：Genetically engineered pig-to-human liver xenotransplantation 翻译：基因工程猪 - 人肝脏异种移植题目：PARG inhibition halts cholangiocarcinoma progression via the Hippo pathway and enhances response to chemotherapy and immunotherapy 翻译：PARG 抑制通过Hippo 通路阻断胆管癌进展并增强化疗与免疫治疗应答题目：Transcriptomic and epigenetic mechanisms controlling cholangiocyte transdifferentiation into hepatocytes 翻译：调控胆管细胞转分化为肝细胞的转录组与表观遗传机制 GUT 题目：MTFP1 drives pancreatic cancer liver metastatic colonisation by regulating mitochondrial metabolism reprogramming 翻译：MTFP1 通过调控线粒体代谢重编程驱动胰腺癌肝转移定植题目：Oleic acid promotes lung injury in hypertriglyceridaemia-associated acute pancreatitis via the PIEZO1/NR4A1/CPT1A axis impairing endothelial fatty acid oxidation 翻译：油酸通过 PIEZO1/NR4A1/CPT1A 轴损伤内皮细胞脂肪酸氧化，加重高甘油三酯血症相关性急性胰腺炎的肺损伤题目：E-cadherin loss in Cd44-positive gastric cells initiates diffuse gastric cancer in a murine model 翻译：小鼠模型中 Cd44 阳性胃上皮细胞E‑钙黏蛋白缺失可启动弥漫型胃癌发生题目：Spatial profiling of patient-matched HER2 positive gastric cancer reveals resistance mechanisms to targeted therapy 翻译：患者配对 HER2 阳性胃癌的空间组学分析揭示靶向治疗耐药机制 GASTROENTEROLOGY 题目：Gastric Organoid-Based Ectopic and Orthotopic In Vivo CRISPR Screening for Tumor Suppressors in Gastric Cancer 翻译：基于胃类器官的异位及原位体内 CRISPR 筛选胃癌肿瘤抑制基因题目：Postoperative Ileum Transcriptomics Implicate Sex-Biased Mechanisms in Crohn’s Disease Recurrence 翻译：术后回肠转录组学提示克罗恩病复发中存在性别差异机制题目：Fecal Detection of Calprotectin Subunits Links Inflammatory Bowel Disease Activity With Chronicity of Intestinal Inflammation 翻译：粪便钙卫蛋白亚基检测将炎症性肠病活动度与肠道炎症慢性化相关联题目：The Gut Microbiome at the Onset of Inflammatory Bowel Disease: A Systematic Review and Unified Bioinformatic Synthesis 翻译：炎症性肠病发病时的肠道微生物组：一项系统评价与统一生物信息学整合分析题目：Mutational Landscape of Colorectal Tumors From Individuals With Unexplained Adenomatous or Serrated Colorectal Polyposis 翻译：原因不明腺瘤性或锯齿状结肠息肉病患者结直肠肿瘤的突变图谱题目：Clusterin Drives Fiber Endocytosis by Mesothelial Cells to Resolve Liver Fibrosis 翻译：簇蛋白驱动间皮细胞摄取纤维以缓解肝纤维化题目：Endoscopic Ultrasound-Guided Choledochoduodenostomy vs Endoscopic Retrograde Cholangiopancreatography in Malignant Distal Biliary Obstruction to Prevent Postprocedural Pancreatitis: A Randomized Trial 翻译：内镜超声引导下胆管十二指肠吻合术 vs 内镜逆行胰胆管造影用于恶性远端胆道梗阻以预防术后胰腺炎：一项随机试验题目：Utility of Serum Biomarkers in Addition to Ultrasound for Early Detection of Hepatocellular Carcinoma in High-Risk Patients: A Randomized Controlled Trial 翻译：高危患者中血清生物标志物联合超声用于肝细胞癌早期检测的价值：一项随机对照试验题目：Changes in Liver Disease Etiology Support a Lower Alpha-Fetoprotein Threshold for Hepatocellular Carcinoma Screening 翻译：肝病病因变化支持降低甲胎蛋白阈值用于肝细胞癌筛查 6.呼吸病学 LANCET RESPIRATORY MEDICINE（本周无更新） EUROPEAN RESPIRATORY JOURNAL（本周无更新） 7.感染与微生物 LANCET INFECTIOUS DISEASES（本周无更新） LANCET MICROBE（本周无更新） NATURE MICROBIOLOGY 题目：Gut microbial ammonia enhances colonic acetylcholine levels to regulate intestinal motility 翻译：肠道微生物产生的氨升高结肠乙酰胆碱水平并调节肠道动力题目：Conserved CD4+ T cell staphylococcal and streptococcal epitopes enable broad-acting vaccines in mice 翻译：保守的 CD4⁺T 细胞葡萄球菌与链球菌表位可在小鼠中实现广谱疫苗作用题目：Longitudinal plasma metabolomics reveals a role for taurine in asymptomatic malaria and seasonal persistence 翻译：纵向血浆代谢组学揭示牛磺酸在无症状疟疾与季节性持续感染中的作用题目：Candida aurisvacuolar calcium pump mediates fluconazole efflux and resistance evolution 翻译：耳念珠菌液泡钙泵介导氟康唑外排与耐药进化题目：Human immunodeficiency virus-associated gut microbiome impacts systemic immunodeficiency and susceptibility to opportunistic gut infection 翻译：人类免疫缺陷病毒相关肠道微生物组影响全身性免疫缺陷及机会性肠道感染易感性 MICROBIOME 题目：Comparative analysis of rumen metagenomes with dietary supplementation of 3-nitrooxypropanol revealed divergent modes of action in hydrogen metabolism and reductant pathways between beef and dairy cattle 翻译：日粮添加 3‑硝基氧丙醇的瘤胃宏基因组比较分析揭示肉牛与奶牛在氢代谢及还原通路中存在不同作用模式题目：Microbiota-derived propionate suppresses Salmonella virulence gene expression via LuxS quorum sensing 翻译：微生物组来源的丙酸通过 LuxS 群体感应抑制沙门菌毒力基因表达题目：Association between the gut microbiome and plasma metabolites linked to vocalization-based temperament in Merino sheep 翻译：美利奴绵羊肠道微生物组与血浆代谢物的关联和基于发声的气质相关题目：Cross-kingdom genomic variation in chicken gut microbiomes: insights from China’s diverse local breeds 翻译：鸡肠道微生物组的跨界基因组变异：来自中国多样地方品种的启示 JOURNAL OF INFECTION（本周无更新） 8.公共卫生和流行病学 LANCET PUBLIC HEALTH（本周无更新） LANCET GLOBAL HEALTH 题目：Global estimates of tuberculosis incidence during pregnancy and postpartum: a rapid review and modelling analysis 翻译：全球孕期及产后期结核病发病率估计：一项快速综述与模型分析题目：Characterising progression and regression patterns across the spectrum of tuberculosis: a multistate modelling approach 翻译：结核病全疾病谱进展与转归模式特征：多状态模型研究题目：Avoidable deaths through the primary prevention, early detection, and curative treatment of cancer worldwide: a population-based study 翻译：全球通过癌症一级预防、早期筛查与根治性治疗可避免的死亡：一项基于人群的研究题目：Effective cataract surgical coverage in adults aged 50 years and older: empirical estimates from population-based surveys in 68 countries and modelled estimates for 2000–30 翻译：50 岁及以上成人有效白内障手术覆盖率：来自68 国人群调查的实证估计及2000–2030年模型预测题目：Early assessment of maternal bleeding: development and validation of a prognostic model predicting death and near miss 翻译：孕产妇出血早期评估：预测死亡与危重不良事件预后模型的建立与验证题目：Low-dose aspirin for preventing intrauterine growth restriction and pre-eclampsia in sickle cell pregnancy in Nigeria (PIPSICKLE): a randomised controlled trial 翻译：尼日利亚镰状细胞病孕妇使用小剂量阿司匹林预防胎儿生长受限与子痫前期（PIPSICKLE）：一项随机对照试验题目：Evaluation of fluorometholone as adjunctive medical therapy for trachomatous trichiasis surgery (FLAME): a parallel, double-blind, randomised controlled field trial in the Jimma Zone, Ethiopia 翻译：氟米龙作为沙眼性倒睫手术辅助药物治疗的评估（FLAME）：埃塞俄比亚吉马地区平行、双盲、随机对照现场试验题目：Effectiveness of behavioural tobacco cessation interventions with and without pharmacotherapy among people living with HIV in Viet Nam: a three-arm pragmatic randomised controlled trial 翻译：越南 HIV 感染者中联合或不联合药物治疗的行为戒烟干预效果：三臂实用性随机对照试验题目：Prevalence and outcomes of intrinsic capacity impairments assessed using the WHO Integrated Care for Older People (ICOPE) framework in The Gambia, South Africa, and Zimbabwe: a cross-sectional study 翻译：采用 WHO 老年人综合照护（ICOPE）框架评估冈比亚、南非与津巴布韦内在能力受损的患病率与结局：一项横断面研究题目：Measuring the impact of global research and development investment in product development partnerships: a case study on return on investment in antimalarial drug development 翻译：评估全球研发投入对产品开发伙伴关系的影响：抗疟药物研发投资回报案例分析题目：Cost and cost-effectiveness of ivermectin mass drug administration for malaria control in Kwale county, Kenya: a modelling analysis of a cluster-randomised trial 翻译：肯尼亚夸勒县伊维菌素大规模给药用于疟疾防控的成本及成本效果：整群随机试验模型分析 9.内科学 JAMA INTERNAL MEDICINE（本周无更新） ANNALS OF INTERNAL MEDICINE 题目：Effectiveness and Safety of Statins in Type 2 Diabetes According to Baseline Cardiovascular Risk 翻译：根据基线心血管风险分层分析他汀类药物在2 型糖尿病中的有效性与安全性题目：Once-Weekly Oral Islatravir Plus Lenacapavir Versus Daily Oral Bictegravir, Emtricitabine, and Tenofovir Alafenamide in Persons With HIV-1 翻译：每周一次口服伊司拉韦 + 来那卡帕韦对比每日口服比克替拉韦/ 恩曲他滨/ 丙酚替诺福韦治疗HIV‑1 感染者题目：Integrating Methadone Services Into Primary Care in Ukraine: Two-Year Outcomes From a Randomized Trial 翻译：将美沙酮服务整合至乌克兰初级保健：一项随机试验的2 年结局题目：Diagnostic Follow-up of Positive Results on Low-Dose Computed Tomography Screening in the Medicare Population 翻译：美国医保人群低剂量 CT 筛查阳性结果后的诊断随访题目：Eligibility and Prognostic Performance of Smoking Duration–Based Versus Pack-Year–Based U.S. National Lung Cancer Screening Criteria Across Racial and Ethnic Groups 翻译：美国国家肺癌筛查标准中：基于吸烟年限vs 基于包年的适用人群与预后表现在不同种族/ 族裔间的对比题目：The Incubation Periods of Mpox Virus Clade Ib 翻译：猴痘病毒 Ib 分支的潜伏期 10.血液学 LANCET HAEMATOLOGY（本周无更新） 11.牙科与口腔外科 JOURNAL OF CLINICAL PERIODONTOLOGY（本周无更新）

2026-02-22

·Biotech前瞻

口服SERD药物新突破：罗氏全口服组合疗法申报上市

点击蓝字关注我们本期看点在全球范围内，乳腺癌已取代肺癌成为女性最常见的恶性肿瘤，其中雌激素受体阳性（ER+）/HER2阴性亚型约占病例的70%。内分泌治疗联合CDK4/6抑制剂是晚期患者的标准一线方案，但耐药性——尤其是ESR1基因突变导致的耐药——成为临床治疗的主要瓶颈。对于经治后进展的患者，选择非常有限，通常只能转向化疗。近年来，新一代口服选择性雌激素受体降解剂（SERD）的出现，为这类患者带来了新的希望。近期，罗氏（Roche）的Giredestrant上市申请获FDA受理，而另一款在研药物Palazestrant（OP-1250）也已进入III期临床（SERD口服创新单药进入三期，乳腺癌耐药患者的希望之光），标志着该领域迎来重要进展。本期内容 01 罗氏：首个全口服SERD组合疗法在望 02 四款药物完成三期，一款已获批 03 Palazestrant：双重机制攻克耐药 04 总结与展望【01 罗氏：首个全口服SERD组合疗法在望】 2026年2月20日，罗氏宣布其自主研发的口服SERD药物Giredestrant的上市申请（NDA）已获美国食品药品监督管理局（FDA）受理。该申请寻求批准Giredestrant联合依维莫司（everolimus），用于治疗既往接受过内分泌疗法、且携带ESR1突变的ER+/HER2-局部晚期或转移性乳腺癌患者。处方药使用者费用法案（PDUFA）的目标审评日期定为2026年12月18日。若获批，该组合将成为CDK4/6抑制剂经治后患者可用的首个全口服SERD方案。 Giredestrant是一种下一代口服选择性雌激素受体降解剂和完全拮抗剂。其作用机制是通过阻止雌激素与雌激素受体（ER）结合，并诱导受体降解，从而抑制癌细胞的生长。此次申报基于III期evERA研究的积极数据。结果显示，在意向治疗（ITT）人群中，Giredestrant联合依维莫司组经研究者评估的中位无进展生存期（PFS）为8.77个月，显著优于对照组的5.49个月（风险比HR=0.56）。在ESR1突变亚组中，疗效更为显著，Giredestrant组中位PFS达到9.99个月，对照组为5.45个月（HR=0.38）。安全性方面，联合疗法耐受性良好，不良事件特征与各单药已知安全性一致，未出现新的安全信号。 02 四款药物完成三期，一款已获批目前，全球已有四款口服SERD药物顺利完成III期临床研究，形成了激烈的竞争格局：艾拉司群（Elacestrant，Menarini）：其III期EMERALD研究选择的对照方案为氟维司群或阿那曲唑或来曲唑或依西美坦。 Imlunestrant（礼来）：其III期EMBER-3研究选择的对照方案为氟维司群联合依西美坦。该药物已率先于2025年9月在美国获批上市，用于治疗至少一线内分泌疗法后疾病进展且携带ESR1突变的ER+/HER2-晚期或转移性乳腺癌成人患者。 Camizestrant（阿斯利康）：其III期SERENA-6研究选择的对照方案为阿那曲唑或来曲唑联合哌柏西利或阿贝西利或瑞柏西利。 Giredestrant（罗氏）：如上所述，其III期evERA研究采用联合依维莫司的方案，目前正在审评中。其中，礼来的imlunestrant已成为该类别中首个获批的单药口服SERD，而罗氏的Giredestrant则有望成为首个获批的全口服联合方案。【03 Palazestrant：双重机制攻克耐药】与此同时，另一款颇具潜力的在研药物Palazestrant（OP-1250）也取得了重要进展。 Palazestrant与传统的内分泌治疗药物有着根本的不同。它同时具有完全雌激素受体拮抗剂（CERAN）和选择性雌激素受体降解剂（SERD）两种功能。这种双重作用机制使Palazestrant能够更彻底地阻断雌激素信号通路，而且不受ESR1突变状态的影响。这意味着无论患者是否出现ESR1突变，药物都能发挥作用，这对于解决耐药问题尤为重要。基于I/II期研究的积极数据，Palazestrant已正式进入III期临床开发阶段。一项首次人体、开放标签、多中心的Ib/II期试验纳入了146例既往至少接受过一线内分泌治疗的ER+/HER2-转移性乳腺癌患者。在推荐剂量（120mg/天）下，所有患者的临床获益率（CBR）达到46%，而在ESR1突变患者中，CBR进一步提高至58.6%。整体患者的中位PFS为4.8个月，ESR1突变患者则延长至5.6个月。安全性良好，大多数治疗相关不良事件为1-2级，最常见的是恶心、呕吐和疲劳，耐受性极佳。基于这些鼓舞人心的结果，III期OPERA-01临床试验已经启动。这是一项国际多中心、随机、开放标签研究，旨在比较Palazestrant单药与标准内分泌治疗在ER+/HER2-晚期乳腺癌患者中的疗效和安全性，主要终点为无进展生存期，预计2026年下半年公布顶线结果。此外，Palazestrant的联合治疗策略也在探索中。2024年欧洲肿瘤内科学会（ESMO）会议上公布的数据显示，Palazestrant联合CDK4/6抑制剂ribociclib，在既往接受过CDK4/6抑制剂治疗的患者中，6个月无进展生存率达到68%。未来，OPERA-02试验将进一步评估该联合方案用于一线治疗的潜力。 04 总结与展望从imlunestrant的获批上市，到Giredestrant的审评推进，再到Palazestrant等药物的三期临床布局，口服SERD药物赛道正呈现出百花齐放的竞争态势。这些进展共同指向一个目标：为内分泌耐药，特别是CDK4/6抑制剂经治后进展的ER+/HER2-乳腺癌患者，提供更有效、更方便（口服）且耐受性更佳的治疗选择。随着2026年多项关键临床数据的陆续揭晓，这些创新疗法有望重塑晚期乳腺癌的治疗格局，为全球数百万患者带来新的曙光。用通俗语言讲透医学知识的科普账号，欢迎关注。 ★

临床3期临床2期上市批准

2026-02-22

·拾遗百草园

【STTT重磅】PFS 16.6个月！国产新型CDK2/4/6抑制剂三期告捷，数据碾压对照组

核心提要：近日，《信号转导与靶向治疗》（Signal Transduction and Targeted Therapy, IF=40.8）发表了一项由中国学者主导的重磅 III 期临床研究成果。由殷咏梅教授、江泽飞教授领衔的团队，公布了我国自主研发的新型 CDK2/4/6 抑制剂——Culmerciclib（TQB3616）联合氟维司群治疗既往内分泌治疗失败的 HR+/HER2- 晚期乳腺癌（ABC）的期中分析数据。研究结果显示，Culmerciclib 组的研究者评估中位 PFS 达到惊人的 16.6 个月，相比安慰剂组（7.5 个月）延长了一倍以上，疾病进展或死亡风险大幅降低了 64%（HR=0.36）。这一“多靶点联合阻断”策略是否将为耐药后的乳腺癌患者开辟一条新路？让我们深入解读这项研究。01 研究背景：CDK4/6 抑制剂时代的隐忧与破局在激素受体阳性（HR+）、人表皮生长因子受体 2 阴性（HER2-）的晚期乳腺癌治疗中，CDK4/6 抑制剂（CDK4/6i）联合内分泌治疗已确立为一线及二线的标准方案。然而，随着帕博西利（Palbociclib）、瑞波西利（Ribociclib）、阿贝西利（Abemaciclib）等药物的广泛应用，临床医生面临着两个无法回避的痛点：必然产生的获得性耐药：几乎所有患者最终都会对 CDK4/6i 产生耐药并进展。耐药机制的复杂性：新兴证据表明，CDK2 的代偿性激活是导致 CDK4/6i 耐药的关键逃逸路径。当 CDK4/6 被抑制时，肿瘤细胞会通过上调 Cyclin E/CDK2 复合物，继续磷酸化 Rb 蛋白，推动细胞周期从 G1 期强行进入 S 期，从而导致治疗失败。临床未满足的需求：目前的上市药物主要针对 CDK4/6。如果能开发出一种同时抑制 CDK2、CDK4 和 CDK6 的药物，是否就能阻断这条关键的逃逸通路，带来更持久的生存获益？ Culmerciclib（TQB3616）正是基于这一理念设计的 First-in-class 口服选择性 CDK2/4/6 抑制剂。它不仅保留了对 CDK4/6 的高效抑制（且对 CDK4 选择性优于 CDK6），更引入了对 CDK2 的强效抑制活性（IC50 为 2.4 nM），旨在通过“多药理学（Polypharmacology）”策略克服耐药。02 研究设计：聚焦中国人群的严谨验证这项随机、双盲、安慰剂对照的 III 期临床试验（NCT05375461）在中国 56 个中心开展。入组人群：既往接受过内分泌治疗（±化疗）后进展的 HR+/HER2- 局部复发或转移性乳腺癌女性患者。分组：293 例患者按 2:1 随机分配至：试验组：Culmerciclib (180 mg QD) + 氟维司群对照组：安慰剂 + 氟维司群分层因素：内脏转移、绝经状态、既往内分泌治疗敏感性。主要终点：研究者评估的无进展生存期（PFS）。关键入组特征：该研究纳入了约 23.2% 既往接受过晚期化疗的患者，且涵盖了原发性内分泌耐药人群（约 21.5%），真实反映了临床难治性患者的现状。03 核心亮点：数据惊艳，全面碾压期中分析数据截止至 2024 年 1 月 16 日，中位随访时间为 13.8 个月。结果显示，Culmerciclib 交出了一份极其亮眼的答卷。1. PFS 获益显著，刷新预期中位 PFS：Culmerciclib 组高达 16.6 个月 vs 安慰剂组 7.5 个月。风险比（HR）：0.36 (95% CI: 0.26-0.51; P<0.001) 。这意味着联合治疗组将疾病进展或死亡的风险降低了 64% 。独立评审（IRC）数据：IRC 评估的 HR 为 0.42，与研究者评估高度一致，证实了结果的稳健性。临床启示：在既往二线治疗的同类研究中（如 PALOMA-3 研究中帕博西利组 PFS 约为 9.5 个月，对照组 4.6 个月），本研究对照组达到了 7.5 个月（可能与入组患者既往治疗线数及氟维司群优异表现有关）。即便在对照组表现出色的基础上，Culmerciclib 依然实现了 PFS 的倍增，显示出强劲的抗肿瘤效力。2. 肿瘤缓解率（ORR）大幅提升客观缓解率（ORR）：40.2% vs 12.1% (P<0.001)。临床获益率（CBR）：76.3% vs 50.5%。起效迅速：对于有可测量病灶的患者，近半数（46.4%）实现了肿瘤缩小。这对于肿瘤负荷大、急需缓解症状的患者尤为重要。3. 广泛的亚组获益无论患者特征如何，Culmerciclib 均显示出一致的疗效优势：内脏转移患者：HR = 0.45。肝转移患者：HR = 0.49。原发性内分泌耐药患者：HR = 0.39。这部分人群通常预后极差，Culmerciclib 的显著获益提示其可能克服深度的内分泌耐药。既往接受过化疗：HR = 0.20。对于化疗后进展的患者，该药表现出极强的控制力，风险降低了 80%。 HER2 低表达（HER2-low）：HR = 0.31。4. 安全性画像：CDK4 偏向性的优势 Culmerciclib 的设计具有 CDK4 偏向性（CDK4-biased），这一特性使其在安全性上呈现出独特的谱系：骨髓毒性相对温和：尽管中国人群通常对骨髓抑制更敏感，但本研究中 **≥3 级中性粒细胞减少症发生率为 24.7%**。这一数据显著低于帕博西利（PALOMA-3 研究中约为 66%）和瑞波西利，且无发热性中性粒细胞减少症发生。这使得临床管理更为简便。胃肠道反应需关注：最常见的不良反应为腹泻（任意级别 87.1%），发生率与阿贝西利相似。但绝大多数腹泻通过止泻药或剂量调整可控，无人因腹泻终止治疗。这提示尽管腹泻高发，但耐受性尚可。04 深度讨论：机制创新带来的临床思考为什么是“CDK2/4/6”？本研究最大的理论突破在于验证了同时阻断 CDK2 的临床价值。传统 CDK4/6 抑制剂的短板：阿贝西利虽然对 CDK2 有微弱抑制作用，但主要还是依赖 CDK4/6 抑制。帕博西利和瑞波西利则对 CDK2 几乎无活性。 Culmerciclib 的策略：通过强效抑制 CDK2，直接封锁了肿瘤细胞利用 Cyclin E/CDK2 复合物绕过 G1/S 检查点的企图。数据印证：16.6 个月的 PFS 显著长于目前已知的二线治疗数据，这在很大程度上支持了“多靶点联合封锁（Polypharmacology）”比单一通路封锁更有效的假说，尤其是在可能存在 CDK2 激活导致的内分泌耐药背景下。并不是“1+1=2”的简单叠加多靶点药物研发中最担心的是毒性叠加。令人欣慰的是，Culmerciclib 并没有因为增加了 CDK2 靶点而出现不可控的全新毒性。其安全性特征主要表现为 CDK4 抑制相关的胃肠道反应（类似阿贝西利）和较轻的骨髓抑制，证明了这种分子设计的成药性。05 局限性与未来展望：我们还需要什么？尽管数据亮眼，但作为严谨的临床/科研人员，我们需客观看待目前的局限性，这也是未来研究的方向： 1. 目标人群的“错位”与未来挑战本研究人群：入组患者既往主要接受内分泌治疗或化疗，均未接受过 CDK4/6 抑制剂治疗。这与 PALOMA-3 研究的人群相似。临床现实：目前临床上绝大多数 HR+ 晚期患者在一线已经使用了 CDK4/6 抑制剂（如帕博西利、阿贝西利等）。关键问题：Culmerciclib 能否在“后 CDK4/6i 时代”力挽狂澜？即对于帕博西利或阿贝西利耐药后的患者，换用 Culmerciclib 是否有效？好消息：基于其抑制 CDK2 的机制，理论上它正是为克服 CDK4/6i 耐药而生。行动：目前已有一项 II 期临床试验（NCT06702618）正在招募既往接受过 CDK4/6 抑制剂治疗的患者，其结果将是决定 Culmerciclib 能否成为真正“耐药克星”的关键。 2. 总生存期（OS）数据尚不成熟截至期中分析，OS 数据尚未成熟。虽然 18 个月 OS 率在数值上优于对照组（79.0% vs 73.9%），但差异尚未达到统计学显著（P=0.188）。我们需要更长时间的随访来确认 PFS 获益能否转化为最终的生存获益。 3. 生物标志物的缺乏本研究暂未公布详细的生物标志物分析。未来需要探索哪些患者更能从 CDK2 抑制中获益（例如 Cyclin E 高表达？Rb 状态？），以实现更精准的患者分层。06 总结：从“跟随”到“超越” Culmerciclib III 期临床研究的成功，不仅是中国原研药的胜利，更是乳腺癌靶向治疗理念的一次重要验证。对临床医生的启示：强效新选择：对于既往未接受过 CDK4/6 抑制剂的二线治疗患者（如因经济原因或药物可及性），Culmerciclib 联合氟维司群提供了目前已知的最长 PFS 获益之一（16.6 个月）。关注难治人群：对于原发性内分泌耐药、有内脏转移或化疗失败的患者，该药展现出令人印象深刻的缓解率和控制能力，可能优于传统 CDK4/6 抑制剂。安全性管理：临床应用中需重点关注腹泻管理（类似阿贝西利），但无需过度担心严重的骨髓抑制（优于帕博西利）。一句话总结：Culmerciclib 凭借独特的 CDK2/4/6 三重抑制机制，在晚期乳腺癌二线治疗中实现了 PFS 的突破性延长，有望成为克服内分泌耐药的又一利器，期待其在 CDK4/6 抑制剂经治耐药人群中的进一步数据披露。参考文献：Yin, Y., Zhang, Q., Sun, T., et al. Novel CDK2/4/6 inhibitor culmerciclib (TQB3616) plus fulvestrant in previously treated, HR-positive, HER2-negative advanced breast cancer: a randomized, double-blind, phase 3 trial. Sig Transduct Target Ther 10, 414 (2025).

临床3期临床失败临床2期放射疗法临床结果

100 项与哌柏西利相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D10372	哌柏西利	L01XE33	DB09073

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
复发性乳腺癌	日本	Pfizer Japan, Inc.	2017-09-27
HR阳性/HER2阴性乳腺癌	美国	Pfizer Inc.	2016-02-19
ER阳性/HER2阴性乳腺癌	美国	Pfizer Inc.	2015-02-03

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
HPV相关鳞状细胞癌	临床3期	美国	Pfizer Inc.	2022-04-06
头颈部鳞状细胞癌	临床3期	美国	Pfizer Inc.	2022-04-06
转移性头颈部鳞状细胞癌	临床3期	美国	Pfizer Inc.	2022-04-06
PIK3CA突变的乳腺癌	临床3期	美国	F. Hoffmann-La Roche Ltd.	2020-08-28
PIK3CA突变的乳腺癌	临床3期	中国	F. Hoffmann-La Roche Ltd.	2020-08-28
PIK3CA突变的乳腺癌	临床3期	阿根廷	F. Hoffmann-La Roche Ltd.	2020-08-28
PIK3CA突变的乳腺癌	临床3期	澳大利亚	F. Hoffmann-La Roche Ltd.	2020-08-28
PIK3CA突变的乳腺癌	临床3期	比利时	F. Hoffmann-La Roche Ltd.	2020-08-28
PIK3CA突变的乳腺癌	临床3期	巴西	F. Hoffmann-La Roche Ltd.	2020-08-28
PIK3CA突变的乳腺癌	临床3期	加拿大	F. Hoffmann-La Roche Ltd.	2020-08-28

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT02947685 (PATINA \| AFT-38, CTgov)	临床3期	HER2阳性转移性乳腺癌 \| ER阳性乳腺癌	518	fulvestrant+Letrozole+palbociclib+pertuzumab+Exemestane+trastuzumab+anastrozole (Arm A)	齋醖觸壓範範衊糧憲夢(餘壓顧夢構構襯廠衊齋) = 鏇鹹遞夢壓醖窪製築顧簾蓋糧衊範範襯網觸夢 (齋鹹積糧鹹憲構壓餘鑰, 遞構範網選憲鑰繭膚構 ~ 艱鬱積壓簾壓艱齋憲廠) 更多	-	2026-02-12
				fulvestrant+Letrozole+pertuzumab+Exemestane+anastrozole (Arm B)	齋醖觸壓範範衊糧憲夢(餘壓顧夢構構襯廠衊齋) = 範鹹糧鬱鬱願製願窪願簾蓋糧衊範範襯網觸夢 (齋鹹積糧鹹憲構壓餘鑰, 遞艱淵鑰網廠淵顧夢鹽 ~ 積繭遞艱範廠範憲糧夢) 更多
NCT02947685 (PATINA, Pubmed \| N Engl J Med)	临床3期	HR阳性/HER2阳性乳腺癌维持 hormone-receptor-positive \| HER2-positive	518	Palbociclib + maintenance HER2-targeted and endocrine therapies	艱鬱製範鹽鹹齋顧鑰窪(壓艱齋鏇壓顧繭廠齋繭) = 衊襯遞鹹簾築簾製鬱淵願構積廠鹽襯構選積淵 (齋膚製製製窪積顧壓餘 ) 更多	积极	2026-01-29
				maintenance HER2-targeted and endocrine therapies	艱鬱製範鹽鹹齋顧鑰窪(壓艱齋鏇壓顧繭廠齋繭) = 鏇鹹壓糧壓蓋繭壓夢淵願構積廠鹽襯構選積淵 (齋膚製製製窪積顧壓餘 ) 更多
NCT02513394 (PALLAS, SABCS2025)	临床3期	HR阳性/HER2阴性乳腺癌辅助 HR+ \| HER2-	5,736	Palbociclib + Endocrine Therapy	齋淵膚壓壓遞齋膚鑰繭(夢窪蓋網蓋繭築顧廠範) = 鬱衊艱構鬱壓蓋夢鏇艱窪鹽鑰窪繭憲淵衊獵鹹 (築顧網範夢積範壓膚顧 ) 更多	不佳	2025-12-11
SABCS2025	N/A	HR阳性/HER2阴性乳腺癌一线 HR+ \| HER2-	323	Palbociclib + Endocrine Therapy	齋廠願鹹繭醖鹹艱顧網(壓糧蓋網遞繭齋選築築) = 鬱鏇製襯積願鑰衊淵遞齋糧獵顧鏇選憲醖製淵 (願鹹鹽蓋觸範範網淵窪 ) 更多	积极	2025-12-10
SABCS2025	N/A	HR阳性/HER2阴性乳腺癌一线 HR+/HER2–	8,076	Palbociclib plus an aromatase inhibitor (AI)	鹹顧鹹構遞構壓觸壓衊(構衊膚製構網壓鏇夢獵) = 醖壓顧窪簾憲顧鑰蓋獵築範鹽艱構膚選衊窪願 (鹽醖壓範憲襯鹹顧構餘, 48.7 ~ 53.1) 更多	积极	2025-12-10
				an aromatase inhibitor (AI)	鹹顧鹹構遞構壓觸壓衊(構衊膚製構網壓鏇夢獵) = 衊獵艱鹽壓夢構鹹願襯築範鹽艱構膚選衊窪願 (鹽醖壓範憲襯鹹顧構餘, 39.8 ~ 44.7) 更多
NCT03870919 (palatine, SABCS2025)	临床2期	ER阳性/HER2阴性乳腺癌 ER positive \| HER2 negative	191	Palbociclib + letrozole combination therapy	膚膚夢獵獵築築淵夢遞(鹽鏇鹹築衊淵鏇淵衊鑰) = 構製鹽膚淵鹽鏇鑰鹹鑰淵艱憲艱鏇願夢積餘齋 (製餘獵願壓製積積鏇衊 ) 更多	不佳	2025-12-10
SABCS2025	N/A	HR阳性/HER2阴性乳腺癌一线 HR+/HER2-	2,267	Palbociclib + Endocrine Therapy	蓋窪艱鑰範廠遞糧糧觸(鏇構壓膚衊鏇窪糧構範) = 獵憲衊鑰淵壓遞構築積範範膚壓觸鹹選齋衊壓 (齋鹽築襯網壓廠壓艱獵, 47.4 ~ 52.3) 更多	积极	2025-12-10
				Palbociclib + Endocrine Therapy (Age <65)	蓋窪艱鑰範廠遞糧糧觸(鏇構壓膚衊鏇窪糧構範) = 繭憲壓襯餘選築壓製積範範膚壓觸鹹選齋衊壓 (齋鹽築襯網壓廠壓艱獵, 49.3 ~ 56.5) 更多
SABCS2025	N/A	HR阳性/HER2阴性乳腺癌一线	82	First-line CDK4/6 inhibitors	蓋餘艱膚憲鑰壓顧積窪(積憲願夢範顧鹹鹹網獵) = 積蓋願鏇窪壓窪膚膚積顧壓願鏇壓觸鬱齋選製 (鏇觸膚鑰製顧壓壓艱顧, 1.0 ~ 55.4) 更多	积极	2025-12-10
PROMISE (SABCS2025)	N/A	ER阳性/HER2阴性乳腺癌二线 \| 一线 HR+ \| HER2-	58	palbociclib + letrozole (1L)	遞顧廠廠襯範顧網選鹹(壓鹹夢鬱窪願範觸襯選) = 鹽鹹築壓構製鏇觸廠齋齋獵襯蓋鏇製衊壓繭獵 (顧淵鑰艱範繭鹹艱鏇簾, 50.3 ~ 100) 更多	积极	2025-12-10
				palbociclib + fulvestrant (2L)	遞顧廠廠襯範顧網選鹹(壓鹹夢鬱窪願範觸襯選) = 醖鏇選觸願選廠選淵鹽齋獵襯蓋鏇製衊壓繭獵 (顧淵鑰艱範繭鹹艱鏇簾, 31.0 ~ 69.5) 更多
SABCS2025	N/A	HR阳性/HER2阴性乳腺癌 HR+ \| HER2-	84	Palbociclib (HR+/HER2- advanced breast cancer)	製艱顧醖糧鬱鬱範獵鬱(蓋鑰蓋憲襯艱鹽襯選糧) = 鏇窪鹹網餘鹽範餘衊齋窪壓選鏇遞鏇壓構繭築 (繭觸製網鏇繭夢糧繭鬱 ) 更多	积极	2025-12-10
				Ribociclib (HR+/HER2- advanced breast cancer)	製艱顧醖糧鬱鬱範獵鬱(蓋鑰蓋憲襯艱鹽襯選糧) = 遞鑰選選壓醖齋製鑰獵窪壓選鏇遞鏇壓構繭築 (繭觸製網鏇繭夢糧繭鬱 ) 更多